Skip to main content
VERA logo

VERA · Vera Therapeutics, Inc.

Track VERA — free
$26.75 +1.17 (+4.57%)
Market Cap
$1.93B
Shares
72.30M
Volume · Nov 19 1.05M Avg daily vol (3M) 1.95M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$26.75 Open$25.60 Day$25.08–27.00 52W close$25.58–55.67 Avg vol 30d1.5M Short int12.1M · 16.8% of shares · 8.5d Short vol64% Last earningsNov 5, 2026 DataMay 2021–Nov 2026 Filing10-Q · Nov 5

Up next

Nov 4, 2027 Est · unconfirmed · in 50 wks

Latest documents

2026
Nov 10
Investor event
Trutacna launch reaches 700 patient start forms

Vera reported 700 patient start forms for Trutacna, described its early launch in the United States as strong, and plans to file in Europe in the first quarter of next year.

4 source passages
We at Vera are now at an inflection point with our first approved drug We reported 700 patient start forms, so an indicator of demand. launch looks strong in the early days. we'll be filing in Europe in the first quarter of next year. Open the document at this passage
Nov 5
Earnings call
Trutacna generated $10.3 million in first partial quarter

Vera Therapeutics reported $10.3 million in Trutacna revenue and approximately 700 patient start forms. It submitted an SBLA seeking full FDA approval, anticipated in mid-2027, supported by a 76% reduction in kidney disease progression risk through 104 weeks.

5 source passages
Good day, and welcome to the Vera Therapeutics Business Update and Financial Results webcast for the quarter ended September 30, 2026. Net product revenue from sales of Schutachna was $10.3 million for the third quarter of 2026, our first partial quarter of commercial sales. Since the accelerated approval of Trutacna on July 7th, we have received approximately 700 patient start forms to date. These results form the basis of the recently submitted SBLA seeking full approval of Trutacna in adults with primary IgA nephropathy, which is anticipated in mid-2027. Trutacna held the rate of kidney function decline to a physiologic level and reduced the risk of kidney disease progression by 76% compared with placebo through 104 weeks. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
TRUTAKNA wins FDA approval and launches product sales

Vera Therapeutics’ TRUTAKNA received FDA accelerated approval on July 7, 2026, for adults with primary IgAN at risk for progression; it generated $10.3 million in product revenue through September 30, 2026, while requesting full approval on November 3, 2026.

Revenue $10.28M Net loss $93.71M Diluted EPS -$1.30
Read from the MD&A section
3 source passages
On July 7, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to TRUTAKNA to reduce proteinuria in adults with primary IgAN at risk for disease progression. For the three and nine months ended September 30, 2026, we recorded net product revenue of $10.3 million from sales of TRUTAKNA. On November 3, 2026, we submitted a supplemental Biologics License Application to the FDA requesting potential full FDA approval in mid-2027. Open the document at this passage
Nov 5
Current report 8-K
TRUTAKNA generates $10.3 million revenue; sBLA submitted

Vera Therapeutics reported $10.3 million in TRUTAKNA revenue; approximately 700 Patient Start Forms were received. ORIGIN 3 showed a 76% reduction in progression risk versus placebo through two years, and an sBLA was submitted to the FDA for full approval.

Financial results
3 source passages
TRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net product revenue in Q3. ORIGIN 3 final efficacy analysis demonstrated stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression versus placebo through two years; data was presented as a late-breaking oral presentation at the opening plenary session at ASN Kidney Week 2026 with a simultaneous publication in The New England Journal of Medicine. Completed supplemental Biologics License Application (sBLA) submission to the FDA on November 3, 2026 for full approval of TRUTAKNA in adults with primary IgAN, based on the ORIGIN 3 final efficacy analysis. Open the document at this passage
Oct 22
Investor event
Virtual Investor Event: ASN Kidney Week 2026

Vera Therapeutics reported a 76% reduction in composite kidney progression through week 104 and an annualized eGFR difference of 5 mL per minute per year for atachycept. An FDA submission supporting potential full approval is planned for 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$415.31M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-20.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$308.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+13.0%
Year over year · more shares
Price change (1Y)
-11.5%
Trailing year
Short interest
16.8%
Latest settlement · 8.5 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −12%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 4%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −8%
trailing
6-month return −21%
trailing
YTD return −47%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $30 › 200d $36 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.79% of shares out · ▼ -10.6% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
227 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Weak
EPS growth −69%
Y/Y
Free cash flow $-241.7M
Balance sheet $279.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 59%
annualized · 1-yr
Max drawdown −54%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 5, 2026
Covered lives · by the end of the year 50%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−12% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
4% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $30 › 200d $36 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.79% of shares out · ▼ -10.6% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
227 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $26 Now $27 · 4% Range high $56
vs 200-day avg -25% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Debt facility availability $350M as of November 5, 2026 —
Patient Start Forms (PSFs) 700 to date following TRUTAKNA's accelerated approval —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VERA
Vera Therapeutics, Inc.
this stock
$1.93B -47.2% — — 16.8%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
227
% held
117.4%
Net QoQ
+6.9M sh
Top holder
Deep Track Capital, LP
Held Float
View
Held by Funds
Fund positions
203
View
Short & Settlement
Short Interest Falling
Shares short
12.1M
Days to cover
8.5d
Change
-1.4M sh
View
Short Volume
Short vol %
64%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
7
Value
$208
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
41.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-299.6M
EPS diluted
$-4.66
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
20

Vera reported 700 patient start forms for Trutacna, described its early launch in the United States as strong, and plans to file in Europe in the first quarter of next year.

View
Proposed Sales
Value
$2.2M
Shares
64.8K
Filed
Sep 2, 2026
View
Exempt Offerings
Offering
$70.7M
Filed
Feb 25, 2021
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Vera Therapeutics Announces Induc…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
VERA -7.9% -7.9% -21.2% -13.7% -47.2%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -2.4% -1.6% -15.6% -8.4% -52.2%
Key facts CIK 1831828 CUSIP 92337R101 13F (30d) 246 filings 220 filers Visit website Investor relations